Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE

被引：0
作者：
Jagerback, Sandra [1 ]
Gomez, Alvaro [1 ]
Parodis, Ioannis [2 ]
机构：
[1] Karolinska Inst, Div Rheumatol, Dept Med, Stockholm, Sweden
[2] Karolinska Inst, Stockholm, Sweden
来源：
ARTHRITIS & RHEUMATOLOGY | 2022年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0540
引用
收藏
页码：1090 / 1093
页数：4
相关论文
共 50 条
  • [31] Leptomeningeal metastasis from non-small cell lung cancer- a post-hoc analysis from four randomised clinical trials
    Patil, Vijay
    Noronha, Vanita
    Vallathol, Dilip Harindran
    Menon, Nandini
    Mahajan, Abhishek
    Janu, Amit
    Purandare, Nilendu
    Prabhash, Kumar
    ECANCERMEDICALSCIENCE, 2022, 16
  • [32] Efficacy and safety of fremanezumab in patients with migraine and obesity: post-hoc analysis of the phase 3 HALO-LTS and FOCUS clinical trials
    Irimia Sieira, P.
    Torphy, B.
    Ortega, M.
    Barash, S.
    Krasenbaum, L. J.
    Akcicek, H.
    Smith, M.
    Ning, X.
    Campos, V. Ramirez
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [33] Neutropenia and efficacy outcomes in patients with refractory mCRC: A post-hoc analysis of the phase III SUNLIGHT trial
    Prager, G.
    Tabernero, J.
    Fakih, M.
    Ciardiello, F.
    Van Cutsem, E.
    Roby, L.
    Yao, W.
    Choucair, E.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S18 - S19
  • [34] Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares
    Mandell, B. F.
    Fields, T. R.
    Edwards, N. L.
    Yeo, A. E.
    Lipsky, P. E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : 1085 - 1092
  • [35] The efficacy of cariprazine in chronic schizophrenia - post hoc analyses of phase II/III clinical trials
    Falkai, P.
    Dombi, Z.
    Acsai, K.
    Barabassy, A.
    Nemeth, G.
    EUROPEAN PSYCHIATRY, 2022, 65 : S323 - S323
  • [36] Impact of risankizumab on the duration of PASI90 achievement: A post hoc analysis of 4 phase III clinical trials
    Lebwohl, Mark G.
    Soliman, Ahmed M.
    Yang, Hongbo
    Wang, Jessie
    Koenigsberg, Sarah H.
    Anderson, Annika
    Padilla, Bryon
    Pinter, Andreas
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB62 - AB62
  • [37] Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
    Vital, Edward M.
    Merrill, Joan T.
    Morand, Eric F.
    Furie, Richard A.
    Bruce, Ian N.
    Tanaka, Yoshiya
    Manzi, Susan
    Kalunian, Kenneth C.
    Kalyani, Rubana N.
    Streicher, Katie
    Abreu, Gabriel
    Tummala, Raj
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (07) : 951 - 961
  • [38] Pirfenidone Delays the Prescription of Concomitant Drugs in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Japanese Phase III Clinical Trial
    Suzuki, A.
    Sakaguchi, H.
    Ebina, M.
    Azuma, A.
    Ogura, T.
    Taguchi, Y.
    Suga, M.
    Takahashi, H.
    Sugiyama, Y.
    Kudoh, S.
    Nukiwa, T.
    Miyazawa, S.
    Sakamoto, K.
    Kondoh, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [39] A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis
    Abe, Koji
    Itoyarna, Yasuto
    Tsuji, Shoji
    Sobue, Gen
    Aoki, Masashi
    Doyu, Manabu
    Hamada, Chikuma
    Togo, Masanori
    Yoneoka, Takatomo
    Tanaka, Masahiko
    Akimotot, Makoto
    Nakamura, Kazue
    Takahashi, Fumihiro
    Kondo, Kazuoki
    Yoshino, Hiide
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2017, 18 : 11 - 19
  • [40] Predictors of Sustainability of Response With Cenobamate: Post-hoc Subset Analysis of a Phase 3, Open-Label, Study
    Stern, Sean
    Wechsler, Robert
    Kerr, Wesley T.
    Wade, Clarence T.
    Vossler, David G.
    Rosenfeld, William E.
    NEUROLOGY, 2023, 100 (17)
12345